title: Pomalidomide: when expectations are understated.
authors.affiliation: Department of Clinical & Molecular Biomedicine, Haematology Section, University of Catania, Catania, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
authors.affiliation: Department of Clinical & Molecular Biomedicine, Haematology Section, University of Catania, Catania, Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Conticello
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019233:Retreatment; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide; C467566:pomalidomide
keywords: drug resistance; immunomodulatory drugs; multiple myeloma; pomalidomide